Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 19/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067328 | 1.00 | P2RY12 (0.47) | P2RY12KDM1ACYP2C9 | |
| SCHEMBL5002653 | 0.75 | P2RY12 (0.55) | P2RY12CYP2C9 | |
| SCHEMBL10074060 | 0.72 | P2RY12 (0.79) | P2RY12CYP2C9 | |
| SCHEMBL6755877 | 0.68 | P2RY12 (0.69) | P2RY12 | |
| SCHEMBL6755887 | 0.68 | P2RY12 (0.67) | P2RY12 | |
| SCHEMBL6758860 | 0.68 | P2RY12 (0.59) | P2RY12 | |
| SCHEMBL7000233 | 0.67 | P2RY12 (0.57) | P2RY12 | |
| SCHEMBL2066476 | 0.65 | P2RY12 (0.80) | P2RY12CYP2C9 | |
| SCHEMBL10074056 | 0.65 | P2RY12 (0.80) | P2RY12CYP2C9 | |
| SCHEMBL6621749 | 0.65 | P2RY12 (0.53) | P2RY12KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148385-B2 | Substituted [1,2,3] triazolo[4,5-d]pyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-03 | — | — | US | claimed |
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | US | claimed |
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312257-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885KDM1A 3524/4885CYP2C9 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.